Medstream360 members only

To view this video and learn more about the procedure please Login or Register.
Membership is free!

The Mount Sinai Hospital

1468 Madison Avenue, New York,
New York 10029

CoreValve Evolut-R TAVR (29mm) via Percutaneous Femoral Access

Core valve TAVR

An 86 year-old male presented with progressive shortness of breath– NYHA class III, with a history of hypertension, III vessel CAD s/p PCI, Asthma/COPD, BPH, Glaucoma, and pleural effusion s/p thoracotomy. TTE revealed severe AS, peak/mean aortic gradient = 108/62 mmHg, AVA = 0.5 sq cm, aortic peak velocity = 5.1 m/sec and LVEF 61%. CT angio showed minimum diameters of 0.8 x 1.0 cm for right and 0.8 x 0.9 cm for left common femoral arteries and aortic annulus of 2.8 X 2.0 cm (average 2.4 cm). The STS risk mortality is 4.4 % and the Logistic Euroscore mortality is 13.14 %. Patient was determined to be high risk for surgical AVR due to COPD and frailty. Patient is now planned for CoreValve Evolut-R TAVR (29mm) via percutaneous femoral access under conscious sedation.


Case Presentation


Lorem ipsum dolor sit amet consectetur adipisicing elit. A, dignissimos?